These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 10593713)

  • 1. The development of a standardised screening protocol for the in vivo assessment of rifampicin bioavailability.
    McIlleron H; Gabriels G; Smith PJ; Fourie PB; Ellard GA
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S329-35; discussion S351-2. PubMed ID: 10593713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent bioequivalence studies on fixed-dose combination anti-tuberculosis drug formulations available on the global market.
    Pillai G; Fourie PB; Padayatchi N; Onyebujoh PC; McIlleron H; Smith PJ; Gabriels G
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S309-16; discussion S317-21. PubMed ID: 10593710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modification to improve efficiency of sampling schedules for BA/BE testing of FDC anti-tuberculosis drugs.
    Gabriels GA; McIlleron H; Smith PJ; Folb PI; Fourie PB
    Int J Tuberc Lung Dis; 2007 Feb; 11(2):181-8. PubMed ID: 17263289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential use of urinary excretion data for assessing the relative bioavailability of rifampicin in fixed dose combination anti-tuberculosis formulations.
    Pillai G; Ellard GA; Smith PJ; Fourie PB
    Int J Tuberc Lung Dis; 2001 Aug; 5(8):691-5. PubMed ID: 11495257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.
    Agrawal S; Singh I; Kaur KJ; Bhade SR; Kaul CL; Panchagnula R
    Int J Pharm; 2004 May; 276(1-2):41-9. PubMed ID: 15113612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative bioequivalence study of rifampicin and isoniazid combinations in healthy volunteers.
    Padgaonkar KA; Revankar SN; Bhatt AD; Vaz JA; Desai ND; D'Sa S; Shah V; Gandewar K
    Int J Tuberc Lung Dis; 1999 Jul; 3(7):627-31. PubMed ID: 10423226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma pooling to expedite bioequivalence estimation of rifampicin in fixed dose combinations.
    Panchagnula R; Parmar J; Kaur JK; Singh I; Bhade SR
    Methods Find Exp Clin Pharmacol; 2006 Apr; 28(3):161-7. PubMed ID: 16810342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of rifampicin bioequivalence in a three-drug FDC by WHO and indian protocols: effect of sampling schedule and size.
    Agrawal S; Kaur KJ; Singh I; Bhade SR; Kaul CL; Panchagnula R
    Int J Tuberc Lung Dis; 2005 Jan; 9(1):75-80. PubMed ID: 15675554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The WHO simplified study protocol in practice: investigation of combined formulations supplied by the WHO.
    Panchagnula R; Kaur KJ; Singh I; Kaul CL
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S336-42; discussion S351-2. PubMed ID: 10593714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral bioavailability of rifampicin, isoniazid, ethambutol, and pyrazinamide in a 4-drug fixed-dose combination compared with the separate formulations in healthy Chinese male volunteers.
    Xu J; Jin H; Zhu H; Zheng M; Wang B; Liu C; Chen M; Zhou L; Zhao W; Fu L; Lu Y
    Clin Ther; 2013 Feb; 35(2):161-8. PubMed ID: 23410999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishment of a reference formulation for bioequivalence assessment of rifampicin-containing FDCs: an essential step towards improving tuberculosis treatment.
    Ashokraj Y; Singh I; Kaur KJ; Kohli G; Bhade SR; Varma MV; Kaul CL; Panchagnula R
    Int J Tuberc Lung Dis; 2005 Jul; 9(7):791-6. PubMed ID: 16013776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality assurance: protocol for assessing the rifampicin bioavailability of combined formulations in healthy volunteers.
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S284-5. PubMed ID: 10593705
    [No Abstract]   [Full Text] [Related]  

  • 13. Plasma pooling: utility in expediting bioequivalence assessment of rifampicin-containing fixed-dose combinations.
    Ashokraj Y; Singh I; Kaur KJ; Kohli G; Bhade SR; Varma MV; Kaul CL; Panchagnula R
    Int J Tuberc Lung Dis; 2005 Jun; 9(6):697-9. PubMed ID: 15971401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relative bioavailability of rifampicin, isoniazid and ethambutol from a combination tablet vs. concomitant administration of a capsule containing rifampicin and a tablet containing isoniazid and ethambutol.
    Schall R; Müller FO; Duursema L; Groenewoud G; Hundt HK; Middle MV; Mogilnicka EM; Swart KJ
    Arzneimittelforschung; 1995 Nov; 45(11):1236-9. PubMed ID: 8929247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The evaluation of rifampicin bioavailabilities of fixed-dose combinations of anti-tuberculosis drugs: procedures for ensuring laboratory proficiency.
    Ellard GA
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S322-4; discussion S351-2. PubMed ID: 10593711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of rifampicin bioequivalence in fixed-dose combinations using the WHO/IUATLD recommended protocol.
    Panchagnula R; Agrawal S; Kaur KJ; Singh I; Kaul CL
    Int J Tuberc Lung Dis; 2000 Dec; 4(12):1169-72. PubMed ID: 11144460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A bioequivalence comparison of two formulations of rifampicin (300- vs 150-mg capsules): An open-label, randomized, two-treatment, two-way crossover study in healthy volunteers.
    Chik Z; Basu RC; Pendek R; Lee TC; Mohamed Z
    Clin Ther; 2010 Sep; 32(10):1822-31. PubMed ID: 21194606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relative bioavailability of rifampicin in a three-drug fixed-dose combination formulation.
    Milán-Segovia RC; Domínguez-Ramírez AM; Jung-Cook H; Magaña-Aquino M; Romero-Méndez MC; Medellín-Garibay SE; Vigna-Pérez M; Romano-Moreno S
    Int J Tuberc Lung Dis; 2010 Nov; 14(11):1454-60. PubMed ID: 20937187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma pooling methodology as a faster and cheaper tool to evaluate bioequivalence of rifampicin component of FDCs of antitubercular drugs.
    Panchagnula R; Sharma A; Agrawal S
    Pharmacol Res; 2003 Dec; 48(6):655-63. PubMed ID: 14527833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative bioavailability of rifampicin and isoniazid in fixed-dose combinations and single-drug formulations.
    Hao LH; Guo SC; Liu CC; Zhu H; Wang B; Fu L; Chen MT; Zhou L; Chi JY; Yang W; Nie WJ; Lu Y
    Int J Tuberc Lung Dis; 2014 Dec; 18(12):1505-12. PubMed ID: 25517820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.